Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TGTX
STRONG BUYTG Therapeutics, Inc. · Healthcare · United States · $8.5B · Avg Vol: $161M/d
COMPANY DESCRIPTION
TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell mediated diseases, particularly multiple sclerosis and B-cell lymphomas. The company operates in a highly specialized pharmaceutical niche, with its competitive edge reliant on the efficacy and approval of its proprietary drug candidates like ublituximab (Briumvi). As a clinical-stage company with an approved product, it addresses areas of high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8M | 233.7M | 329.0M | 616.3M | 504.9% | 700.3M | 941.4M | 1.2B | 41.1% |
| EPS | -1.46 | 0.09 | 0.16 | 3.10 | 486.9% | 2.95 | 1.72 | 3.21 | 1.8% |
| Shares | 146.4M | 151.5M | 156.2M | 158.8M | +8.5% | 153.1M | — | — | — |
| Debt | 83.1M | 110.8M | 253.7M | 253.7M | 45.1% | 753.6M | — | — | — |
| Equity | 58.6M | 160.5M | 222.4M | 648.0M | 122.8% | — | — | — | — |
| Op CF | -176.2M | -31.4M | -40.5M | -24.8M | — | -14.0M | — | — | — |
| Inv CF | -20.0M | -50.7M | -1.0M | 13.8M | — | — | — | — | — |
| Fin CF | -0.4M | 72.7M | 128.5M | -89.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TGTX | TG Therapeutics, Inc.(you) | $8.5B | 83 | STRONG BUY |
| KRYS | Krystal Biotech, Inc. | $11.0B | 84 | STRONG BUY |
| HALO | Halozyme Therapeutics, Inc. | $8.9B | 90 | STRONG BUY |
| CORT | Corcept Therapeutics Incorporated | $9.4B | 73 | BUY |
| BMRN | BioMarin Pharmaceutical Inc. | $11.4B | 74 | BUY |
| 0K6R.L | Neurocrine Biosciences, Inc. | $16.9B | 81 | STRONG BUY |
| LGND | Ligand Pharmaceuticals Incorporated | $6.1B | 73 | BUY |
| TECH | Bio-Techne Corporation | $11.1B | 67 | BUY |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.3B | 73 | BUY |
| EXEL | Exelixis, Inc. | $13.8B | 97 | STRONG BUY |
Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%